Actively Recruiting
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma
Led by OriCell Therapeutics Co., Ltd. · Updated on 2024-08-02
81
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary effectiveness of an anti-GPRC5D CAR-T cell product called OriCAR-017 in adults with relapsed or refractory multiple myeloma. This Phase I/II open-label study is the first clinical trial of OriCAR-017 in the United States by OriCell Therapeutics Co., Ltd., aiming to find suitable dosing and assess early treatment results in this patient group. The study includes a Phase I dose escalation stage with three different doses given as a single intravenous infusion to up to 18 participants. This is followed by a dose expansion stage with 10-15 participants and then a Phase II stage that may include up to 48 participants. Each participant receives one infusion of OriCAR-017 to evaluate its effects and safety. Participants will be closely monitored for up to two years after treatment. Researchers will assess the maximum tolerated dose and dose-limiting toxicities within 28 days after infusion. They will also study how the drug moves through and affects the body, measure response duration, progression-free survival, overall survival, and other response rates. Regular evaluations include laboratory tests, clinical assessments, and safety monitoring throughout the study period.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable of giving signed informed consent
- Aged 18 to 75 years inclusive at screening
- Expected survival period greater than 12 weeks
- Diagnosed with multiple myeloma according to IMWG criteria (2016 version)
- For IgG type MM, serum M protein greater than 10 g/L; for IgA, IgD, IgE, or IgM type MM, serum M protein greater than 5 g/L
- Urine M protein level greater than 200 mg/24 hour
- For light chain type MM, serum free light chain greater than 100 mg/L with abnormal K/λ ratio
- Presence of extramedullary lesions larger than 1 cm in diameter
- For Phase I dose-escalation: received at least 3 prior lines of therapy, prior BCMA-Ag+ therapies exposure, refractory to last therapy
- For Phase I dose-expansion and Phase II: prior exposure to BCMA therapies including bispecific antibodies, antibody-drug conjugates, or CAR-T
- Adequate hematologic, renal, hepatic, pulmonary, and cardiac function
- Willingness of subject and partner to use effective contraception until 2 years post infusion
You will not qualify if you...
- Pregnant or breastfeeding
- Seropositive for HIV or active Hepatitis B or C infection
- Known active or prior CNS involvement
- History of autoimmune diseases causing organ damage or requiring systemic immunosuppressive therapy in past 2 years
- Presence of uncontrolled active infection
- Received autologous hematopoietic stem cell transplantation within 8 weeks of screening or plans to undergo during study
- Received allogeneic stem cell therapy
- Any condition interfering with evaluation of the investigational medicinal product
- Received Bendamustine treatment within 1 year prior to screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days
Participants receive a single intravenous infusion of the OriCAR-017 CAR-T cell product.
1 infusion visit and multiple follow-up visits within 28 days
Duration - Up to 2 years
Participants are monitored for safety, pharmacokinetics, pharmacodynamics, and efficacy outcomes after treatment.
Regular follow-up visits over 2 years
Trial Site Locations
Total: 1 location
1
Northside Hospital
Atlanta, Georgia, United States, 30342
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here